Liquid Biopsy Market - By Biomarkers, By Product, By Disease Indication, By Clinical Application, By Technology, By End Use - Global Forecast, 2025 - 2034

Liquid Biopsy Market Size

The global liquid biopsy market was valued at USD 4.8 billion in 2024 and is projected to grow from USD 5.5 billion in 2025 to USD 20.7 billion by 2034, expanding at a CAGR of 15.8%, according to the latest report published by Global Market Insights Inc. This steady growth is driven by the continuous technological advancements in cancer diagnostics, increasing preference for non-invasive disease diagnosis, growing prevalence of cancer worldwide, and rising awareness regarding early disease diagnosis.

Major companies in the industry include Thermo Fisher Scientific, Illumina, Guardant Health, F. Hoffmann-La Roche, and QIAGEN. They actively invest in research and development to improve the precision and reliability of liquid biopsy technologies. Top players in this market leverage advanced platforms such as next-generation sequencing and AI-driven analytics to actively strengthen their competitive position in the liquid biopsy market.
 

The market increased from USD 2.9 billion in 2021 to USD 4.1 billion in 2023. This growth can be primarily attributed to the growing prevalence of cancer worldwide and rising awareness regarding early disease diagnosis. Global programs such as the WHO’s Global Initiative for Cancer Early Diagnosis and the National Cancer Institute’s (NCI) Affordable Cancer Technologies Program play a crucial role in promoting timely cancer detection, especially in low-resource settings.
 

These initiatives focus on improving access to screening, enhancing diagnostic infrastructure, and supporting the development of cost-effective technologies. By prioritizing early diagnosis, such initiatives create a favorable environment for the adoption of innovative tools like liquid biopsy, which offer non-invasive, accurate, and scalable solutions, ultimately driving growth in the global liquid biopsy market.
 

The growing prevalence of cancer worldwide is one of the key factors aiding in the growth of the liquid biopsy industry. For instance, according to the American Cancer Society, approximately 19 million people are diagnosed with cancer annually worldwide. Also, cancer cases could rise to 33 million by 2050, driven by aging and population growth. The rising global burden of cancer is escalating the need for early and accurate diagnostic solutions. As cancer cases rise globally, healthcare providers increasingly rely on liquid biopsy to deliver early, accurate, and non-invasive diagnostics. This growing demand is directly fueling the expansion of the liquid biopsy market.
 

Additionally, increasing preference for non-invasive disease diagnosis is significantly growing demand for liquid biopsy. Non-invasive diagnosis plays a crucial role in managing cancer among geriatric and pediatric patients, where traditional biopsy procedures may pose significant risks due to age-related frailty or developmental sensitivity. For instance, according to the World Health Organization, an estimated 400,000 children and adolescents are diagnosed with cancer worldwide each year. In such cases, techniques like liquid biopsy offer a safer, more comfortable alternative for early detection and disease monitoring, enabling timely intervention without physical strain. This growing need for scalable diagnostic solutions is accelerating the adoption of non-invasive technologies in the global healthcare market.
 

A liquid biopsy is a diagnostic test that detects and analyzes genetic material, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA, and extracellular vesicles found in bodily fluids, typically blood. It is primarily used in cancer detection, monitoring treatment response, and identifying genetic mutations. Unlike traditional biopsies, it does not require surgical tissue sampling, making it safer, faster, and more comfortable for patients.
 

Liquid Biopsy Market Trends

The market is changing rapidly due to continuous technological advancements in cancer diagnostics.
 

• Microfluidics is revolutionizing liquid biopsy by enabling the precise manipulation of tiny fluid volumes to isolate and analyze circulating tumor DNA (ctDNA) and cells from blood samples. For example, the Target Selector ctDNA EGFR Kit offered by Biocept uses proprietary Switch-Blocker technology to detect EGFR mutations with high sensitivity. This microfluidics-based approach allows for the detection of mutations like L858R, T790M, and Del19 at very low allele frequencies, making it valuable for non-small cell lung cancer (NSCLC) patients who cannot undergo tissue biopsy.
   
• Next-generation sequencing (NGS) has further transformed the liquid biopsy landscape by enabling comprehensive genomic profiling from a simple blood draw. NGS can detect multiple mutations simultaneously, even at low frequencies, offering a powerful tool for early cancer detection, treatment selection, and monitoring of resistance mutations.
   
• For instance, FoundationOne Liquid CDx by F. Hoffmann-La Roche is an FDA-approved liquid biopsy test that enables comprehensive genomic profiling of solid tumors using a simple blood draw. Its primary application is to guide personalized cancer treatment decisions, especially for patients with advanced or metastatic cancers where tissue biopsy may not be feasible. It identifies genetic alterations that are helpful for oncologists to match patients to targeted therapies, making it an important tool in precision oncology.
   
• Market leaders in the liquid biopsy space maintain their position through continuous innovation, strategic collaborations, and robust clinical validation of their technologies. They invest in advanced platforms like microfluidics and next-generation sequencing to enhance diagnostic accuracy and broaden the scope of applications
   

Liquid Biopsy Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on biomarkers, the liquid biopsy market is segmented into circulating tumor cells (CTC), circulating tumor DNA, cell-free DNA, extracellular vesicles, and other biomarkers. The circulating tumor cells segment led this market in 2024, accounting for the highest market share owing to its ability to provide non-invasive sampling and real-time monitoring. This segment was valued at USD 1.9 billion in 2024. In comparison, the circulating tumor DNA, valued at USD 1.5 billion in 2024, is expected to grow to USD 6.4 billion by 2034, with a slightly higher CAGR of 15.6%, supported by its high sensitivity and specificity.
 

• Circulating Tumor Cells (CTCs) are cancer cells that break away from a primary tumor and enter the bloodstream. These cells carry vital information about the tumor’s genetic makeup and behavior. In liquid biopsy, CTCs are isolated from a blood sample using advanced technologies such as microfluidics, immunoaffinity-based capture, and imaging systems.
   
• CTCs are significantly contributing to the growth of the liquid biopsy market by expanding its clinical utility. Their ability to provide real-time insights into tumor evolution and metastasis supports personalized treatment strategies, which are increasingly in demand.
   
• For instance, AdnaTest Select is a liquid biopsy test developed by QIAGEN that isolates circulating tumor cells (CTCs) from blood samples. It uses immunomagnetic enrichment, where magnetic beads coated with antibodies specifically bind to tumor-associated markers on CTCs. This allows for highly selective capture of tumor cells for downstream molecular analysis.
   
• Technological advancements have improved the sensitivity and reliability of CTC detection, encouraging adoption in hospitals, diagnostic labs, and research institutions. Moreover, the growing interest in precision oncology and early cancer detection is driving growth of the market.
   

Based on the product, the liquid biopsy market is segmented into consumables, instruments, and services. The consumables segment is further sub-segmented into kits and reagents, and assay and panels. The consumables segment accounted for the highest market share of 58.9% in 2024.
 

• Consumables such as kits and reagents are pivotal in expanding the market by improving diagnostic precision and enabling early cancer detection. Their role in streamlining workflows and reducing turnaround times makes liquid biopsy more accessible and scalable for clinical and research applications.
   
• Moreover, they support personalized medicine by helping identify actionable mutations and resistance markers, thereby guiding targeted therapies and monitoring treatment response effectively.
   
• An example of such innovation is the QIAGEN EZ1&2 ccfDNA DNA Kit which is an automated solution for extracting high-quality cell-free DNA (cfDNA) from plasma or serum, ideal for liquid biopsy research. It uses magnetic bead-based purification and is compatible with QIAGEN's EZ1 Advanced XL and EZ2 Connect instruments. This kit supports applications such as cancer biomarker discovery, prenatal testing, and transplant monitoring in molecular biology research.
   
• Continued development of consumables such as reagents and kits, and assay and panels, together with integration into clinical workflows, are key drivers of innovation and growth in the consumables segment.
   

Based on the disease indication, the liquid biopsy market is segmented into cancer and non-cancer. Cancer is further segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and other applications. Similarly, the non-cancer segment is further segmented into non-invasive prenatal testing, organ transplantation, and infectious disease testing. The cancer segment accounted for the highest market share of 85.8% in 2024.
 

• The rising global incidence of cancer is a major driver of growth in the liquid biopsy market. As cancer becomes more prevalent, there is a growing demand for early detection and personalized treatment strategies. Liquid biopsy offers a safer, faster, and more patient-friendly alternative to traditional methods, making it increasingly preferred by clinicians and patients.
   
• Among cancers, breast cancer remains the most common cancer among women globally and the second most common cancer overall. In 2022, there were approximately 2.3 million new cases and 670,000 deaths worldwide. The burden is expected to rise significantly, with projections indicating 3.2 million new cases and 1.1 million deaths annually by 2050. These alarming trends underscore the urgent need for scalable, non-invasive diagnostic solutions like liquid biopsy.
   
• Therefore, cancer’s growing global burden is catalyzing innovation and expansion in the market. The shift toward precision medicine and early detection has positioned liquid biopsy as a transformative tool in oncology, particularly for early cancer diagnosis and therapeutic monitoring.
   

Based on the clinical application, the liquid biopsy market is segmented into treatment monitoring, prognosis and recurrence monitoring, treatment selection, and diagnosis and screening. The treatment monitoring segment accounted for the highest market share and was valued at USD 1.9 billion in 2024.
 

• Liquid biopsy plays a critical role in monitoring treatments for malignancies such as colorectal, breast, and lung cancers. Its ability to provide real-time insights into therapy responses enables healthcare professionals to make timely adjustments to treatment plans. Due to its non-invasive nature and effectiveness in detecting resistance mutations, liquid biopsy has become an integral tool in routine oncology care.
   
• Liquid biopsy plays a critical role in therapy monitoring by enabling the detection of new mutations, thereby supporting the development of tailored treatments in the evolving field of precision medicine. For example, the early identification of EGFR resistance in lung cancer facilitates timely treatment modifications. This alignment with personalized treatment strategies is driving increased clinical reliance and widespread adoption of liquid biopsy technologies.
   
• Further, advancements in digital PCR and NGS have significantly improved the sensitivity and turnaround times for therapy monitoring. Automated technologies now enable continuous patient monitoring through frequent and cost-effective testing. These innovations enhance clinical reliability and scalability of liquid biopsy for monitoring applications, driving the revenue growth in the treatment monitoring segment.
   

Based on technology, the liquid biopsy market is segmented into multi-gene parallel analysis (NGS), and single gene analysis (PCR microarrays). Multi-gene parallel analysis (NGS) dominates the market with a share of about 75.8% in 2024.
 

• Next-generation sequencing (NGS) enables simultaneous analysis of multiple genes, offering a comprehensive view of genomic alterations in a single test. This capability is particularly valuable for early multi-cancer detection and personalized cancer treatment, as it identifies actionable mutations, resistance markers, and tumor heterogeneity.
   
• NGS technologies are cost-effective and scalable for high-throughput testing, allowing laboratories to process hundreds of samples simultaneously. This efficiency reduces turnaround times and operational costs, driving widespread clinical adoption, especially within large cancer networks and centralized testing frameworks.
   
• Additionally, NGS supports the integration of transcriptomic, epigenomic, and genomic data in multi-omics approaches. This adaptability positions NGS as a future-ready technology for comprehensive disease profiling, with applications extending beyond oncology to areas such as infectious disease diagnostics, prenatal testing, and transplant monitoring.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the end use, the liquid biopsy market is segmented into hospitals, research laboratories, clinical laboratories, and other end users. The hospitals segment accounted for the highest market share of 42.5% in 2024.
 

• Hospitals play a pivotal role in the market as both end users and facilitators of clinical adoption. Their infrastructure supports the use of advanced technologies like next-generation sequencing (NGS) and AI-based analytics, making them essential nodes in the diagnostic ecosystem.
   
• Hospitals are significantly accelerating the growth of the liquid biopsy market by adopting these tests on a large scale. Hospitals are increasingly collaborating and investing in liquid biopsy solutions, driven by the rising demand for personalized and minimally invasive cancer diagnostics.
   
• A notable example of hospital-industry collaboration is the MSK-ACCESS liquid biopsy test, developed by Memorial Sloan Kettering Cancer Center in partnership with SOPHiA GENETICS. This test analyzes ctDNA from a single blood draw to detect actionable genomic alterations and is now deployed across 34 hospitals worldwide.
   
• As partnerships between hospitals and biotech firms are growing, and as regulatory approvals increase, hospitals will continue to be at the forefront of transforming cancer diagnostics through liquid biopsy.
   

Looking for region specific data?

Download Free PDF

North America Liquid Biopsy Market

North America dominated the market, valued at USD 2 billion in 2024. The market is expected to be valued at USD 8.4 billion by 2034. Accelerating demand for non-invasive disease diagnosis and continuous product launches with a high focus on R&D by the market players are expected to offer unprecedented growth opportunities in the region.
 

• The U.S. liquid biopsy market was valued at USD 1.1 billion and USD 1.2 billion in 2021 and 2022, respectively. In 2024, the market size reached USD 1.7 billion from USD 1.5 billion in 2023.
   
• The country observed a surge in the number of people suffering from cancer over the years. According to the American Cancer Society, in 2025, cancer continues to pose a significant public health and economic challenge in the U.S., with projections indicating over 2 million new cases and approximately 600,000 fatalities nationwide. The highest incidence rates are concentrated in breast, prostate, lung, and colorectal cancers, representing key focal points for healthcare providers, pharmaceutical innovators, and policy stakeholders to focus on to reduce their impact and improve treatment.
   
• Additionally, heightened awareness among clinicians and patients, coupled with strong investment in biotech innovation and supportive government funding for oncology research, is accelerating adoption across hospitals, research institutions, and diagnostic labs across the country.
   

Europe Liquid Biopsy Market

Europe market accounted for USD 1.4 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The market in Europe is experiencing strong growth, driven primarily by the increasing preference for non-invasive disease diagnosis. This shift is fueled by rising cancer prevalence, advancements in biomarker detection technologies, and growing demand for early-stage screening and real-time treatment monitoring.
   
• Germany, France, and the UK are leading countries adopting liquid biopsy tests. These tests offer a minimally invasive alternative to traditional tissue biopsies, enabling clinicians to analyze circulating tumor DNA (ctDNA), RNA, and exosomes from blood samples. Supported by government initiatives, expanding clinical trials, and broader accessibility through digital platforms, liquid biopsy is rapidly gaining traction across hospitals and research institutions throughout these countries in Europe.
   

Germany's liquid biopsy market is projected to experience steady growth between 2025 and 2034.
 

• The market in Germany is expanding steadily, driven by rising incidences of cancer and a strong healthcare infrastructure. For instance, according to the German Centre for Cancer Registry Data (ZfKD), Germany continues to face a high cancer burden, with over 500,000 new cases reported annually, making cancer one of the leading causes of death nationwide.
   
• With advancements in biomarker analysis and next-generation sequencing, German hospitals and research institutions are increasingly adopting liquid biopsy technologies to complement traditional tissue biopsies. Supportive government funding, rising clinical trial activity, and a strong biotech ecosystem are further accelerating market growth across the country.
   

Asia Pacific Liquid Biopsy Market

The Asia Pacific region was valued at USD 1 billion in 2024 and is projected to show a lucrative growth of about 16.7% during the forecast period.
 

• The liquid biopsy market across the Asia-Pacific region is experiencing robust growth, driven by continuous technological advancements in cancer diagnostics. These innovations have significantly improved the accuracy, speed, and accessibility of non-invasive testing methods, making liquid biopsy an increasingly preferred option for early cancer detection and treatment monitoring.
   
• Countries in the region are rapidly adopting these technologies due to rising cancer awareness, expanding healthcare infrastructure, and a growing emphasis on precision medicine. As a result, hospitals, research institutions, and diagnostic labs are integrating liquid biopsy into routine oncology workflows, reshaping the landscape of cancer care in Asia-Pacific.
   

Japan liquid biopsy market is poised to witness lucrative growth between 2025 – 2034.
 

• The country’s aging demographic is a major driver, with 29.1% of the population aged 65 and older as of 2023, according to Statista. This demographic shift is increasing the demand for early and minimally invasive cancer diagnostics, as older patients often require gentler screening methods and more frequent monitoring.
   
• Liquid biopsy offers a safer, faster alternative to traditional tissue biopsies, making it particularly suitable for the elderly population in Japan. Combined with Japan’s advanced healthcare infrastructure, strong investment in precision medicine, and growing adoption of genomic technologies, these factors are expected to significantly accelerate the integration of liquid biopsy into routine clinical practice across the country.
   

Latin America Liquid Biopsy Market

Brazil in Latin America is experiencing significant growth in the market, driven by its rising number of surgical procedures.
 

• According to Brazil’s National Cancer Institute (INCA), breast cancer remains the most frequently diagnosed cancer among women in the country. For the 2023–2025 period, INCA estimates approximately 73,610 new breast cancer cases per year, with an incidence rate of 66.54 per 100,000 women. This high disease burden is expected to drive significant growth in Brazil’s liquid biopsy market, as healthcare providers increasingly seek non-invasive, efficient diagnostic tools to improve early detection and treatment monitoring.
   
• Liquid biopsy offers a promising alternative to traditional tissue biopsies, particularly in regions with limited access to advanced surgical procedures. With rising awareness, expanding oncology infrastructure, and growing investment in precision medicine, Brazil is positioned to accelerate adoption of liquid biopsy technologies across both public and private healthcare sectors.
   

Middle East and Africa Liquid Biopsy Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia's elderly population is rising at a much faster pace than any other segment. It is estimated that the population aged 60 years and above will grow from 2 million (5.9 percent of the total population) in 2020 to 10.5 million by 2050.
   
• This demographic shift is expected to significantly boost the market in the country, as older individuals typically require less invasive, more frequent, and safer diagnostic procedures.
   

Liquid Biopsy Market Share

• The top 5 players, such as Guardant Health, Thermo Fisher Scientific, Illumina, F. Hoffmann-La Roche, and QIAGEN, collectively held 55% of the total market share.

• Leading firms in the market maintain their competitive edge through a combination of biomarker innovation, AI-powered diagnostics, regulatory alignment, and strategic collaborations with oncology centers and diagnostic labs.
   
• Companies like Guardant Health and Illumina are leveraging proprietary ctDNA platforms and machine learning algorithms to enhance early cancer detection and therapy selection, particularly in high-burden cancers such as lung, breast, and colorectal.
   
• Meanwhile, emerging players like Freenome and Lucence Health are gaining traction by offering cost-effective, multi-cancer screening solutions tailored for outpatient clinics and underserved regions. To expand market share, the industry is integrating AI-driven quality control into sequencing workflows to ensure reproducibility and reduce error margins.
   
• The development of ultra-sensitive assays, decentralized testing kits, and smart reporting dashboards is reshaping procurement strategies. Furthermore, the convergence of liquid biopsy with wearable biosensors and remote monitoring platforms is unlocking new opportunities in chronic disease management and home-based oncology care, broadening access and accelerating adoption across diverse healthcare settings.
   

Liquid Biopsy Market Companies

Few of the prominent players operating in the liquid biopsy industry include:

• Angle
• BIOCEPT
• Bio-Rad Laboratories
• EPIGENOMICS
• F. Hoffmann La Roche
• Freenome Holdings
• Guardant Health
• Illumina
• Lucene Health
• MDxHealth
• Menarini Silicon Biosystems
• Myriad Genetics
• Oncimmune
• QIAGEN 
• Thermo Fisher Scientific
   
• Guardant Health

Guardant Health is a pioneer in precision oncology, with its specialty in delivering highly sensitive and comprehensive liquid biopsy solutions for cancer detection and monitoring. The company’s flagship product, Guardant360, exemplifies its innovation by analyzing 739 cancer-related genes using its advanced Guardant Infinity platform, which integrates genomic and epigenomic sequencing for superior sensitivity. Guardant Health’s strength lies in its ability to provide rapid, non-invasive insights into tumor burden and actionable mutations, enabling oncologists to tailor treatments more effectively.
 

• Illumina

Illumina, Inc. plays a pivotal role in the liquid biopsy market through its leadership in next-generation sequencing (NGS) technology, which underpins many of the most advanced diagnostic solutions in oncology. Leveraging high-performance platforms like the NovaSeq X Series, Illumina enables efficient and highly sensitive detection of circulating tumor DNA (ctDNA), even from small sample volumes. A key product, TruSight Oncology ctDNA v2, offers broad cancer biomarker coverage, supporting applications such as therapy selection and disease monitoring.
 

• QIAGEN

QIAGEN plays a key role in the liquid biopsy market by offering comprehensive and automated workflows that streamline sample processing and analysis. Its QIAsymphony DSP Circulating DNA Kit is a notable solution, designed for high-throughput purification of cell-free DNA (cfDNA) from plasma and urine with minimal manual effort. The company supports a broad spectrum of biomarkers, including cfDNA, circulating tumor cells (CTCs), and exosomes, and integrates both PCR and next-generation sequencing (NGS) technologies to enable highly sensitive mutation detection.

Liquid Biopsy Market News:

• In September 2025, Myriad Genetics entered a strategic partnership with SOPHiA GENETICS to co-develop a global liquid biopsy companion diagnostic (CDx). The collaboration was centered on MSK-ACCESS powered by SOPHiA DDM, a ctDNA-based test developed with Memorial Sloan Kettering Cancer Center. This hybrid model was aimed at expanding access to precision oncology testing worldwide.
   
• In April 2025, Guardant Health announced a multi-year global collaboration with Pfizer to integrate its Guardant Infinity smart liquid biopsy platform into Pfizer’s oncology clinical trials. The partnership focused on circulating tumor DNA (ctDNA) monitoring and blood-based epigenomic analyses to advance precision oncology. Additionally, the collaboration extended Guardant’s presence in China through its existing partnership with Adicon Holdings, further strengthening its global footprint in liquid biopsy applications.
   

The liquid biopsy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Biomarkers

• Circulating tumor cells (CTC)
• Circulating tumor DNA
• Cell-free DNA
• Extracellular vesicles
• Other biomarkers

Market, By product

• Consumables
  • Kits and reagents
  • Assay and panels
• Instruments
• Services

Market, By Disease Indication

• Cancer
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Prostate cancer
  • Other cancers
• Non-cancer
  • Non-invasive prenatal testing
  • Organ transplantation
  • Infectious disease testing

Market, By Clinical Application

• Treatment monitoring
• Prognosis and recurrence monitoring
• Treatment selection
• Diagnosis and screening

Market, By Technology

• Multi-gene parallel analysis (NGS)
• Single gene analysis (PCR Microarrays)

Market, By End Use

• Hospitals
• Research Laboratories
• Clinical Laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE